Long-term safety and efficacy of anakinra and canakinumab in patients with familial Mediterranean fever: a single-centre real-life study with 101 patients

Atas, N.; Eroglu, G.; Sodan, H.; Ozturk, B.; Babaoglu, H.; Satis, HASAN; Karadeniz, H.; Guler, A.; Salman, R.; Goker, B.; Ozturk, M.; Haznedaroglu, S.; Tufan, A.

Long-term safety and efficacy of anakinra and canakinumab in patients with familial Mediterranean fever: a single-centre real-life study with 101 patients

Atıf İçin Kopyala

Atas N., Eroglu G. A., Sodan H. N., Ozturk B. O., Babaoglu H., Satis H., ...Daha Fazla

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, cilt.39, sa.5, 2021 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 39 Sayı: 5
Basım Tarihi: 2021
Dergi Adı: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
Anahtar Kelimeler: familial Mediterranean fever, anakinra, canakinumab, efficacy, safety, COLCHICINE-RESISTANT, INTERFERON-ALPHA, AA AMYLOIDOSIS, DOUBLE-BLIND
Gazi Üniversitesi Adresli: Evet

Özet

Objective. Anakinra and canakinumab are the most commonly used agents in colchicine resistant/intolerant patients. In this study we investigated long-term efficacy and safety of anakinra and canakinumab.